胆管癌组织LOXL2 mRNA与Tenascinm-C mRNA表达的临床应用研究

Clinical Application of the Expression of LOXL2 mRNA and Tenascin-C mRNA in Tissues of the Bile Duct Cancer

目的探讨组织赖氨酰氧化酶样蛋白-2(LOXL2)mRNA和Tenascinm-C mRNA表达在胆管癌疾病中的临床应用价值。方法收集35例胆管癌患者(胆管癌组)和28例正常胆管组织(对照组)的血清及临床资料,采用实时荧光定量PCR(real-time-PCR,RT-PCR)技术检测组织LOXL2 mRNA与Tenascin-CmRNA的表达,探讨两标志物的变化与胆管癌疾病之间的关系。结果组织LOXL2 mRNA和Tenascin-C mRNA在胆管癌组中的表达量分别为1.27±0.18,1.39±0.19;在对照组的表达量分别为0.20±0.06,0.23±0.06。胆管癌组组织LOXL2 mRNA与Tenascin-C mRNA的表达与对照组比较显著增高,差异均有统计学意义(t=52.18,56.87,P均<0.01)。胆管癌组两标志物的表达呈正相关性(r=0.687,P<0.01)。结论组织LOXL2mRNA与Tenascin-CmRNA的表达可能成为胆管癌疾病的早期诊断及判断其病程进展的分子标志物。

Objective To explore the clinical application of the expression of LOXL2 mRNA and Tenascin-C mRNA in tissues for the disease with the bile duct cancer. Methods The serum and clinical data in 35 cases of patients with the bile duct cancer （cancer group） and 28 cases of patients with normal bile duct tissue （control group） were collected, used the real-time fluorescent quantitative PCR （real-time-PCR, RT-PCR） technology to detect the expression of LOXL2 mRNA and Tenascin- C mRNA in tissues toobserve the relationship between the changes and the bile duct cancer for the two markers. Results The expression of LOXL2 mRNA and Tenascin-C mRNA in tissues in the cancer group were 1.27=k0. 18 and 1.39±0.19, which of ones in the control group were 0.20±0.06 and 0.23±0.06. In the cancer group,the expression of LOXL2 mRNA and Tenascin-C mRNA in tissues respectively with comparision to those in the control group were significantly higher, the differences had statistical significance（t= 52.18,56.87, P〈0.01）, which of ones in the cancer group was positively related （r=0. 687,P〈0.01）. Conclution The expression of LOXL2 mRNA and Tenascin-C mRNA in tissues may be a molecular targets for the disease with the bile duct cancer in the early diagnosis and judgment of progression in the courses of this disease.